Clinical trial
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical…
NCT00410306 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00410306 |
|---|---|
| Title | Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice |
| Official title | International, Multi-center Post Authorization Surveillance Study on the Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido) |
| Acronym | IPASS Nebido |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Male, Hypogonadism |
| Intervention type | Drug |
| Interventions | Testosterone Undecanoate (Nebido, BAY86-5037) |
| Enrollment | 1,493 |
| Start date | Oct 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Dec 12, 2006 |
| Last update posted | Sep 24, 2010 |
| Countries | Australia, Austria, Bulgaria, Colombia, Czechia, Estonia, Germany, Hong Kong, Indonesia, Italy, Jordan, Kazakhstan and 21 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: